Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II dose-escalation and expansion study of intramuscular HZBio1 in gout
CTR20221761Phase 2Completed
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Dec 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HZBio1 in gout, sponsored by Chongqing Paijin Biotechnology. Started Dec 2022; status: completed.
02
Drugs
HZBio1
03
Conditions
gout
Beyond the preview
Go deeper on CTR20221761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221761.